SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

NGL Fine-Chem - Quaterly Results

21 May 2024 Evaluate
A decent increase of about 31.08% in the sales to Rs. 956.09 millions was observed for the quarter ended March 2024. The sales figure stood at Rs. 729.42 millions during the year-ago period.The company has announced a 27.21% increase in its profits to Rs . 108.50  millions for the  quarter ended March 2024 compared to Rs. 85.29 millions in the corresponding quarter in the previous year.The company reported a good operating profit of 167.60 millions compared to 133.21 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 956.09 729.42 31.08 3289.73 2750.52 19.60 3289.73 2750.52 19.60
Other Income 41.64 26.86 55.03 159.01 76.12 108.89 159.01 76.12 108.89
PBIDT 167.60 133.21 25.82 601.94 356.96 68.63 601.94 356.96 68.63
Interest 4.58 3.22 42.24 13.38 11.97 11.78 13.38 11.97 11.78
PBDT 163.02 129.99 25.41 588.56 344.99 70.60 588.56 344.99 70.60
Depreciation 20.64 19.17 7.67 81.48 78.99 3.15 81.48 78.99 3.15
PBT 142.38 110.82 28.48 507.08 266.00 90.63 507.08 266.00 90.63
TAX 33.88 25.53 32.71 121.89 64.81 88.07 121.89 64.81 88.07
Deferred Tax 1.13 -3.97 -128.46 7.76 -7.30 -206.30 7.76 -7.30 -206.30
PAT 108.50 85.29 27.21 385.19 201.19 91.46 385.19 201.19 91.46
Equity 30.89 30.89 0.00 30.89 30.89 0.00 30.89 30.89 0.00
PBIDTM(%) 17.53 18.26 -4.01 18.30 12.98 40.99 18.30 12.98 40.99

NGL Fine-Chem Share Price

2229.75 -25.30 (-1.12%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×